Most recent findings that modulation of MITF activity can drive phenotype switching in vivo, and abrogating MITF activity in melanoma leads to tumor regression, but a low level of wild-type MITF is oncogenic [27] indicate that further studies are needed. Here, MITF is linked to neoplasm.